This article was originally published on The Limbic Australian patients with multiple myeloma face critical shortcomings in genetic testing at diagnosis and access to new ‘standard of care’ treatments such as daratumumab, a leading haematologist has told a Parliamentary inquiry. Professor Andrew Spencer of Monash University says the current reimbursement model is unsuited to handling...Continue Reading

This article was originally published on Cancer Network Results from a study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting suggested that radiation therapy administered to patients with relapsed or refractory multiple myeloma awaiting CAR T-cells is safe and feasible without worsening rates of severe cytokine release syndrome (CRS), neurotoxicity, or hematologic...Continue Reading

This article was originally published on Cancer Therapy Advisor As the coronavirus disease 2019 (COVID-19) pandemic evolves into subsequent waves in many parts of the world, there are many outstanding questions about the outcomes of infection for patients with multiple myeloma, specifically around the severity of outcomes, prognostic factors, and the effect of different treatments....Continue Reading

This article originally published on Multiple Myeloma Toady ABSTRACT Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to an increasing subset of patients living with long-term...Continue Reading

This article was originally published on Docwire News Sarah Holstein, MD, PhD, associate professor of medicine in the Division of Oncology & Hematology at the University of Nebraska Medical Center, discusses the multiple myeloma (MM) treatment pipeline and how the introduction of these agents may change the treatment landscape. In part two of this interview...Continue Reading

This article was originally posted on Docwire News. DocWire News sat down with Saad Usmani, M.D., MBA, FACP to discuss an indirect treatment comparison study which assesses DARZALEX® (daratumumab) Plus Lenalidomide and Dexamethasone (D-Rd) and Bortezomib-Containing Regimens in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma. To continue reading this article on Docwire News.Continue Reading

This article was originally published on Docwire News Nina Shah, MD, an associate professor in the Department of Medicine at the University of California, San Francisco, discusses immunotherapy agents in the pipeline for multiple myeloma (MM) and how the potential approval of these agents could change the treatment landscape and advance combination therapy. Watch part...Continue Reading

This article was originally published on Targeted Oncology The multiple myeloma treatment paradigm has seen an assortment of therapeutic advances in recent years with agents that have demonstrated the ability to extend survival in patients and improving disease outcomes. However, the severity of the disease continues to linger without a cure, calling for oncologists to...Continue Reading

This article was originally published on The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available...Continue Reading

This article was originally posted on Strathroy Age Dispatch Multiple myeloma was practically a death sentence when Joanne Ternovan was diagnosed. Like many people who had this incurable cancer of the plasma cells, she was given three years to live. That was 22 years ago. “I didn’t think I was going to make it this...Continue Reading